Health news
Topline results were announced from a phase 3 trial evaluating the efficacy and safety of nabiximols oromucosal spray (JZP378) on clinical measures of spasticity in adults with multiple sclerosis. Nabiximols oromucosal spray is an investigational…
Transcranial magnetic stimulation (TMS) may effectively treat depressive symptoms in people with multiple sclerosis (MS), according to preliminary data presented at the 2022 Annual Meeting of the Consortium of Multiple Sclerosis Centers (CMSC) held from…
Baseline neurofilament light chain (NfL) levels may be a biomarker of future lesion activity observed during magnetic resonance imaging (MRI) and relapse risk among patients with multiple sclerosis (MS), according to study results presented at…
Amneal has announced the launch of Lyvispah® (baclofen) oral granules for the treatment of spasticity resulting from multiple sclerosis, particularly for the relief of flexor spasms and concomitant pain, clonus, and muscular rigidity. The gamma-aminobutyric…
The Food and Drug Administration (FDA) has extended the review period for the Biologics License Application (BLA) for ublituximab for the treatment of patients with relapsing forms of multiple sclerosis (RMS). The new Prescription Drug…
Women who experienced childhood sexual and emotional abuse may have an increased risk of developing multiple sclerosis (MS) later in life, according to study findings published in Journal of Neurology, Neurosurgery, and Psychiatry. A Swedish…
Clinical trials have produced remarkable strides in the treatment of multiple sclerosis (MS) in recent decades, especially for patients with the relapsing-remitting form of the disease. For the estimated 15% of patients with progressive forms…
Ublituximab was found to demonstrate consistent no evidence of disease activity (NEDA) among patients with relapsing multiple sclerosis (RMS), according to study findings presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, held…
A significant relationship between Mediterranean diet score and multiple sclerosis (MS)-related disability was established in study findings presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, held from April 2 to April 7…
The Food and Drug Administration (FDA) has cleared the Cionic Neural Sleeve for functional electrical stimulation to provide ankle dorsiflexion and/or plantarflexion in adults with foot drop and/or to assist knee flexion or extension in…
© 2005-2021 Top-Meds - All rights reserved. Our website services, content, and products are for informational purposes only. Top-Meds does not provide medical advice, diagnosis, or treatment. | Medical News 2021